Q4 EPS Forecast for Eledon Pharmaceuticals Cut by Analyst

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Stock analysts at HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings per share of ($0.32) for the quarter, down from their previous forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ FY2025 earnings at ($0.91) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Eledon Pharmaceuticals Price Performance

Shares of ELDN stock opened at $4.07 on Friday. The stock has a market cap of $161.42 million, a P/E ratio of -2.02 and a beta of 0.76. The company has a fifty day moving average price of $3.37 and a two-hundred day moving average price of $2.93. Eledon Pharmaceuticals has a one year low of $1.11 and a one year high of $5.54.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several hedge funds have recently bought and sold shares of ELDN. Clarity Capital Partners LLC acquired a new position in Eledon Pharmaceuticals during the third quarter worth approximately $29,000. Dimensional Fund Advisors LP bought a new stake in Eledon Pharmaceuticals in the 2nd quarter valued at $80,000. Marco Investment Management LLC boosted its position in Eledon Pharmaceuticals by 22.3% during the second quarter. Marco Investment Management LLC now owns 30,344 shares of the company’s stock worth $80,000 after purchasing an additional 5,535 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Eledon Pharmaceuticals by 57.1% in the second quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after purchasing an additional 49,704 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Eledon Pharmaceuticals by 9.7% in the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock valued at $942,000 after purchasing an additional 33,569 shares during the period. 56.77% of the stock is currently owned by institutional investors and hedge funds.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).